Skip to content

Earnings call

Sun Pharmaceutical Industries Q1 FY26 earnings call: Sun Pharmaceutical Industries Limited is planning to launch UNLOXCYT in the US in the second half of FY'26

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company is planning to launch UNLOXCYT in the US in the second half of FY'26. Consolidated sales in the first quarter of FY'26 were Rs. 1,37,861 million, up 10.1% over the last year. The company was ranked No. 1 and held 8.3% market share in the over Rs. 2,302 billion Indian pharmaceutical market as per AIOCD PharmaTrac MAT June 2025. The company launched 4 new generic products in the US in Q1. The company had a consolidated net cash position of $3.1 billion, invested in Board approved securities and earmarked for future investments.

The numbers management gave

Results

  • Consolidated sales in the first quarter of FY'26 were Rs. 1,37,861 million, up 10.1% over the last year.
    Show source
    Sales for the first quarter of FY'26 stood at Rs. 1,37,861 million, registering a growth of 10.1% over the last year.
  • EBITDA margin in the first quarter of FY'26 was 31.1%.
    Show source
    Gross margin was favorable aided by lower material cost due to better product mix and a higher share of sales from the Innovative Medicines.
  • EBITDA in the first quarter of FY'26 was Rs. 43,017 million, up 19.2% over the previous year.
    Show source
    EBITDA for the quarter was Rs. 43,017 million, recording a growth of 19.2% over the previous year.
  • Profit before exceptional items and tax in the first quarter of FY'26 was Rs. 39,908 million, up 16.6% year on year.
    Show source
    Profit before exceptional items and tax stood at Rs. 39,908 million, registering a year-on-year growth of 16.6%.
  • Exceptional items in the first quarter of FY'26 were Rs. 8,180 million, primarily towards impairment of SCD-044 and GXMDL settlement; netting provisions in the books for part of the GXMDL settlement, the balance amount was accounted during the quarter.
    Show source
    During the quarter, exceptional items accounted for Rs. 8,180 million, primarily towards impairment of SCD-044 and GXMDL settlement.
  • Effective tax rate in the first quarter of FY'26 was 24.3%, compared with 16.1% in Q1 FY'25.
    Show source
    Effective tax rate for the quarter was 24.3%, vis-à-vis 16.1% in Q1 FY'25.
Show 20 more statements

Results

  • Adjusted net profit in the first quarter of FY'26 was Rs. 29,961 million, up 5.7% from the corresponding period in the last year.
    Show source
    Adjusted net profit for the quarter was Rs. 29,961 million, which is up by 5.7% from the corresponding period in the last year.
  • Reported net profit in the first quarter of FY'26 was Rs. 22,786 million after exceptional items, compared with Rs. 28,356 million for Q1 FY'25.
    Show source
    Reported net profit for the quarter was Rs. 22,786 million after the exceptional items compared to Rs. 28,356 million for Q1 FY'25.
  • Forex gain in the first quarter of FY'26 was Rs. 2,290 million, compared with a loss of Rs. 505 million during the same period last year.
    Show source
    Forex gain during this quarter was Rs. 2,290 million and this compares to a loss of Rs. 505 million during the same period last year.
  • Other income in the first quarter of FY'26 was Rs. 4,645 million lower than last year, which included interest on income tax refund during the first quarter of FY'25.
    Show source
    Other income during the quarter was Rs. 4,645 million lower than last year, which included interest on income tax refund during the first quarter of FY'25.
  • Adjusted EPS in the first quarter of FY'26 was Rs. 12.50 per share.
    Show source
    Adjusted EPS for the quarter was Rs. 12.50 per share.
  • Formulation sales in India in the first quarter of FY'26 were Rs. 47,211 million, up 13.9% over Q1 last year.
    Show source
    For Q1, the sales of formulation in India were Rs. 47,211 million, recording a growth of 13.9% over Q1 last year.
  • India formulation sales accounted for 34.2% of Sun Pharmaceutical Industries Limited’s total consolidated sales in the first quarter of FY'26.
    Show source
    India formulation sales accounted for 34.2% of total con solidated sales for the quarter.
  • Overall US business grew 1.4% to $473 million in the first quarter of FY'26, driven by its innovative medicines portfolio, with Ilumya, Cequa, Winlevi and Odomzo contributing, offset by decline in generics due to additional competition in certain products.
    Show source
    Our overall US business grew by 1.4% to $473 million for the quarter.
  • The US accounted for 29.3% of Sun Pharmaceutical Industries Limited’s consolidated sales in the first quarter of FY'26.
    Show source
    The US accounted for 29.3% of consolidated sales for the quarter.
  • Branded formulation revenues in emerging markets were $298 million in the first quarter of FY'26, up 5.1% over Q1 last year; underlying growth in constant currency terms was 4%.
    Show source
    Our branded formulation revenues in emerging markets were $298 million, up by 5.1% over Q1 last year.
  • Emerging markets accounted for 18.5% of Sun Pharmaceutical Industries Limited’s total consolidated revenue in Q1.
    Show source
    Emerging markets accounted for 18.5% of total consolidated revenue for Q1.
  • Formulation revenues in the rest of the world were $219 million, up 15.5% over last quarter FY'25.
    Show source
    Formulation revenues in the rest of the world were $219 million, up 15.5% over last quarter FY'25.
  • Rest of the world markets accounted for approximately 13.6% of Sun Pharmaceutical Industries Limited’s consolidated revenue.
    Show source
    Rest of the world markets account for approximately 13.6% of consolidated revenue.
  • Global innovative medicine sales in Q1 FY'26 were up 16.9% to $311 million.
    Show source
    In Q1 FY'26, our global innovative medicine sales were up 16.9% to reach $311 million.
  • Consolidated investments towards R&D in Q1 FY'26 were Rs. 9,029 million, or 6.5% of sales.
    Show source
    Consolidated investments towards R&D for Q1 FY'26 stand at Rs. 9,029 million or 6.5% of sales.
  • CNS growth was in line with India growth and was in the 11% to 12% range.
    Show source
    If I remember correctly, it is 11% to 12% range.
  • Tax rate was around 23.4% currently and is expected to be around 25% for the full year.
    Show source
    And currently it is around 23.4%.
  • Effective tax rate was 14.7% in Q3 FY '25.
    Show source
    Jayashree Satagopan: For the full year, we can consider around 25%.
  • Romania, Russia and South Africa performed well among Sun Pharmaceutical Industries Limited’s larger emerging markets in local currency terms.
    Show source
    Amongst the larger markets in local currency terms, Romania, Russia, South Africa have done well.

Money and capital

  • The company had a consolidated net cash position of $3.1 billion, invested in Board approved securities and earmarked for future investments.
    Show source
    Our balance sheet continues to be strong, with a net cash position of $3.1 billion at the consolidated level, which is invested in Board approved securities and is earmarked for future investments.

What it expects ahead

What management expects

  • The company is planning to launch UNLOXCYT in the US in the second half of FY'26.
    Show source
    We are planning to launch UNLOXCYT in the US in the second half of FY'26.
  • The company plans to file Ilumya after it has the requisite information for filing; it hopes to file the product before the end of this calendar year, but is not 100% sure.
    Show source
    Hopefully, we should be able to file the product before the end of this calendar year.
  • Overall cost of $100 million for the Leqselvi and UNLOXCY launches is estimated to be sustained during FY'26; amortization of acquisition cost will start only when the product is in market, and the company will see Leqselvi from this quarter.
    Show source
    But I think our estimation is that the overall cost of 100 million, we will be sustaining during the year.
  • The company plans to refile the marketing authorization application for Nidlegy at an appropriate time when the requisite information is available.
    Show source
    They plan to refile the application at an appropriate time when they have the requisite information.
  • The company plans to present or publish the Ilumya PSA trial result in a reputed journal before publicly talking about the data.
    Show source
    Dilip Shanghvi: Yes, the plan is to present the data or publish the trial result in a reputed journal before we start publicly talking about the data.
  • The company expects to launch Unloxcyt in the second half of the fiscal year.
    Show source
    Richard Ascroft: We expect to launch in the second half of the fiscal year.

What it is building and selling

Demand and pricing

  • The company was ranked No. 1 and held 8.3% market share in the over Rs. 2,302 billion Indian pharmaceutical market as per AIOCD PharmaTrac MAT June 2025.
    Show source
    Sun Pharma is ranked No. 1 and holds 8.3% market share in over Rs. 2,302 billion Indian pharmaceutical market as per AIOCD PharmaTrac MAT June 2025.
  • Market share in the Indian pharmaceutical market was 8% in the previous period.
    Show source
    Corresponding market share for the previous period was 8%.
  • The company grew higher than IPM for the quarter ending June 2025 and did well across all major represented therapy areas.
    Show source
    For the quarter ending June 2025, we grew higher than IPM and we have done well across all major represented therapy areas.

Segments

  • The company launched 4 new generic products in the US in Q1.
    Show source
    In Q1, we launched 4 new generic products in the US.
  • The company announced the launch of Leqselvi in the United States earlier this month for the treatment of severe alopecia areata.
    Show source
    Earlier this month, Sun Pharma announced the launch of Leqselvi in the United States for the treatment of severe alopecia areata.
  • UNLOXCYT is the first and the only FDA approved PD-L1 treatment for advanced cutaneous squamous cell carcinoma. Replaced by a later filing.

Risks, rules and outside factors

Risks and disputes

  • The company announced that its patent litigation with Incyte relating to Leqselvi was settled, removing the overhang of litigation from the product launch.
    Show source
    We also announced Sun Pharma's settled patent litigation with Incyte relating to Leqselvi, which removed the overhang of litigation from the product launch.
  • The company has three facilities under warning letter from the US FDA: Mohali, Dadra, and Halol.
    Show source
    So, we currently have three facilities that are under warning letter from the US FDA.
  • Facilities in Baska, Ohm, Hungary, Haifa, Brampton, and Billerica continue to supply to the U.S. and are in a compliant status with US FDA.
    Show source
    So, all of these facilities continue to supply and are in a compliant status with US FDA.

Everything else said on the call

Group structure

  • The company has completed its acquisition of Checkpoint Therapeutics; the acquisition adds UNLOXCYT to Sun Pharmaceutical Industries Limited’s innovative portfolio. Replaced by a later filing.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Kunal Dhamesha: Hi, thank you for the opportunity and good evening. The first one on the Ilumya successful trial on PSA. Could you provide some timeline? I know it's at a filing stage, but how should we look at when the filing could happen and then when can we expect, you know, what is the potential timeline here for the developed markets like US, Europe? And also if you could provide some data points in terms of the proportion of patients reaching ACR 20, 50 or 70 at week 24, that would be great.

    Answer, dilip shanghvi

    Dilip Shanghvi: Yes, the plan is to present the data or publish the trial result in a reputed journal before we start publicly talking about the data. And I think the regulatory team is working with the CRO to ensure that as soon as we have all the requisite information b ecause we have currently only the topline data, but once we have the requisite information for filing, the plan is to file. Hopefully, we should be able to file the product before the end of this calendar year. But that's not something that I am 100% sure about, but that's the plan.

  2. Question

    Kunal Dhamesha: Sure, thank you for that. And the second question is regarding, we had suggested that there would be incremental costs related to launch of LEQSELVI and UNLOXCYT in FY'26, which we had pegged at around $100 million. So, have we seen that impact in this quarter and will it be more spread across the quarters or will it be high at the time of launch and then comes down from there on?

    Answer, dilip shanghvi

    Dilip Shanghvi: So, in addition to the actual cost outgo, there will also b e amortization of the cost of the acquisition and that will start only when the product is in market. So, we will see Leqselvi from this quarter. But I think our estimation is that the overall cost of 100 million, we will be sustaining during the year. You don't see that much in the first quarter, but it will start coming.

  3. Question

    Kunal Dhamesha: So, just a clarification. So, this 100 million includes both the cash and amortization charge or it's just the spending and then amortization would be separately? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY26 Earnings Call Transcript 06:30 pm July 31, 2025 Dilip Shanghvi: No, I think it will be the direct cost 100 million.

    Answer, jayashree satagopan

    Jayashree Satagopan: Amortization will be factored in our guidance that we have given.

    Answer, dilip shanghvi

    Dilip Shanghvi: But we don't give profit guidance.

  4. Question

    Neha Manpuria: Thanks for taking my question. My first question is on Leqselvi. Now that we have launched the product, how should we look at, I mean, what would be the key milestones in terms of traction of the product? Because if you look at the other two competing products, we have seen very different trends from IQVIA in terms of the prescription trends. If you can just help us in terms of when you think we get to a point where we are comfortable with formulary coverage, how much time would that take roughly?

    Answer, richard ascroft

    Richard Ascroft: Yes. So, we just launched Leqselvi a couple weeks ago. We are very encouraged by the early results. We have seen good receptivity with healthcare professionals and patients with our messaging. We already have patients that are going through our hub, which is our support program. And we already have our initial commercial prescriptions. We are in ongoing discussions with payors, which have been very positive.

    Answer, richard ascroft

    And as I said, we are encouraged by what we have seen with the first two weeks in the market.

  5. Question

    Neha Manpuria: And Rick, in your view, when do you think this starts converting into revenue contributions, once you see that formulary coverage, would it take usually nine months? Would it be a year out? Or, you could start seeing contribution much faster than that, from a revenue ramp up perspective?

    Answer, richard ascroft

    Richard Ascroft: If we plan, we will see some impact this year, this fiscal year.

  6. Question

    Neha Manpuria: Understood. My second question is on the ROW market. That seems to have seen a very strong growth in the quarter. Is there anything, any milestone income, anything in that number or the growth that's strong in the ROW market? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY26 Earnings Call Transcript 06:30 pm July 31, 2025 Richard Ascroft: Could you repeat the question?

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think she's asking about the rest of the world market. So I think the overall, there's no specific event that I can point to. But there may be some one time sales, which may also be responsible. But the overall guidance that we have given includes the performance of the emerging markets and the rest of the world markets.

  7. Question

    Neha Manpuria: Understood. I am sorry if I could squeeze in one more question. On the MFN, based on your discussion, what is the sense of the likelihood of Ilumya getting included in the demonstration project and therefore negotiations on that? Any color on that?

    Answer, dilip shanghvi

    Dilip Shanghvi: Yes, maybe Rick, you can respond because I am away from market that way.

    Answer, richard ascroft

    Richard Ascroft: Yes, I would say we have no further information on the MFN executive order. We have not had any dialogue with the government. We have not been contacted with respect to any products in our portfolio.

  8. Question

    Damayanti Kerai: Hi, good evening and thank you for the opportunity. My question is in the U.S. market. So while we are still waiting for the details, official details to come on the tariff part, but from your side, do you have any thought about improving your manufacturing footprint in the U.S.?

    Answer, richard ascroft

    Richard Ascroft: Maybe I can start. We actually have a significant footprint in the United States already. And at this time, we have no plans to move further manufacturing to the U.S. Damayanti Kerai: If you can indicate broadly what percentage of sales come from your U.S. plant at this point of time, that will be helpful.

    Answer, abhishek sharma

    Abhishek Sharma: That we don't disclose, Damayanti.

  9. Question

    Damayanti Kerai: Okay. But you think the current capacity is good enough for you in case you need to onshore manufacturing and you have no immediate plan to add on here?

    Answer, dilip shanghvi

    Dilip Shanghvi: Yes, I think that would be the right assumption. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY26 Earnings Call Transcript 06:30 pm July 31, 2025 Damayanti Kerai: Okay.

  10. Question

    And my second question is on the Revlimid opportunity. So does 1Q number reflect meaningful contribution from that product? And if you can also comment on the pricing for that product?

    Answer, richard ascroft

    Richard Ascroft: I would say our generics business faces up and downs quarterly due to lenalidomide. If we remove that impact, the U.S. generic business is down quarter-over-quarter and year-over-year. We do see continued pricing pressure for lenalidomide.

Show 25 more questions
  1. Question

    Bino Pathiparampil: Hi. Good evening and good morning. A couple of questions. One, Dilip bhai, were you happy about the topline results from the Ilumya Psoriatic Arthritis study or could it have been better? I am asking this because we have seen the ACR20 numbers which have come fine. But in ACR50 and 70 maybe didn't show much improvement.

    Answer, dilip shanghvi

    Dilip Shanghvi: So I think when you look at the numbers, you also need to look at dosing. What we have in no induction dosing as well as only two injections. So I think it's a very good result considering the dose and the overall safety profile. The doctors with whom we have discussed understand the product because it's a class that they are familiar with. So we are comfortable with these numbers.

  2. Question

    Bino Pathiparampil: Understood. Yes. And just a question on the one-off settlement that you have done. There was this $200 million settlement of Taro. From your footnotes, I understand that you have recognized trading about $62 million in this quarter in Q1. So should I assume that the balance would be recognized in Q2, Q3, etc. as an exceptional item?

    Answer, jayashree satagopan

    Jayashree Satagopan: Let me take this question. Out of the $200 million, we were carrying a provision for part of it in our books from prior years. So netting of that, the balance has been fully accounted in this quarter and therefore we would not see any further exceptional item on this account in the forthcoming quarter. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY26 Earnings Call Transcript 06:30 pm July 31, 2025 Bino Pathiparampil: Got it.

  3. Question

    Shashank Krishnakumar: Hi, thanks for taking my question. My first question was on the domestic business. I think this quarter we have seen a 14% growth on a relatively higher 1Q base. And last few quarters, also if I look at our growth rates, it's not a significant divergence but a marginal divergence versus what secondary sales growth trends would indicate. So I just wanted to understand if the OTC portfolio is now becoming a major part of our domestic piece and probably there are a few sales channels which are not getting captured. Is it what is driving this marginal growth divergence versus what we see in secondary sales trends?

    Answer, kirti ganorkar

    Kirti Ganorkar: The majority of the growth is coming from prescription business. It's not from consumer business.

  4. Question

    Shashank Krishnakumar: Okay, got it. So my second question was, again, last quarter we had indicated that we are looking to launch a few new products in the diabetes and weight loss management space in the domestic market going forward. Just wanted to understand how this will sort of reshape the income and treatment regimen, particularly for diabetes. Because while the incremental opportunity size probably is being talked about, just wanted to understand how the current standard of care treatment could get disrupted when some of these new launches come in starting next year?

    Answer, dilip shanghvi

    Dilip Shanghvi: GLP-1 effect on existing products. So, I think if you look at that way globally, there's a lot of experience about the impact of GLP-1 on sale of existing product, both DPP-4 as well as SGLT-2. So we haven't seen any significant degrowth in those. As a matter of fact, post-generics, I think there is an increase only. So I think if that is repeated in India, there should be no problem.

  5. Question

    Surya Narayan Patra: Thanks for this opportunity, sir. Taking the GLP point further, could you give some sense about your participation in the first wave of commercialization of GLP product in Canada and Brazil?

    Answer, kirti ganorkar

    So we are all working in that direction so that we come first to the market.

  6. Question

    Surya Narayan Patra: Thank you. This is useful. Dilip sir, My second question was about the cash deployment that you are having in the annual report that you have mentioned. So in the recent past, much of the investment, what we have done, it is towards the specialty portfolio. And this time that you are also indicating about your interest beyond that. So could you give some clarity about that? Which are the areas that you would be interested in spending and all that?

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think we have indicated that we will continue to look for opportunities to strengthen our product portfolio in three therapy areas that we are interested in; Ophthalmology, Dermatology and Onc/Derm. Surya Narayan Patra: Okay. And irrespective of the market?

  7. Question

    Surya Narayan Patra: Irrespective of the market, not necessarily U.S. or India?

    Answer, dilip shanghvi

    Dilip Shanghvi: Yes, I mean, generally, this asset is easier to do a global deal.

  8. Question

    Surya Narayan Patra: Okay. Sir, I was just looking at the China development also. We know that we have Ilumya, Ilumetri there through partner, but we have now created our own subsidiary also. If you can add some color to that, those kind of development and interest?

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think it's an option that we are creating without any specific plan at this point.

  9. Question

    Vishal Manchanda: Yes. Thanks for the opportunity and good evening, everyone. With respect to generic Revlimid, we are almost halfway through into CY'25. And there are two quarters to go before the exclusivity expires. So is it fair to assume that you would have sold 50% of your allocated volume quota for the year?

    Answer, richard ascroft

    Richard Ascroft: No, we don't provide product specific guidance. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY26 Earnings Call Transcript 06:30 pm July 31, 2025 Vishal Manchanda: Okay.

  10. Question

    So, do we expect our U.S. formulation run rate to improve from here in the coming quarters?

    Answer, richard ascroft

    Richard Ascroft: Again, we don't provide that level of guidance.

  11. Question

    Vishal Manchanda: Okay. And just one more. So, like, I could see in your annual report that there is a sharp jump in the with respect to India. There's a sharp jump in the neuropsychiatry therapy revenues on a YOY basis. A very sharp jump. So is this almost a Rs. 1 ,000 crores, in fact, on a YOY basis?

    Answer, kirti ganorkar

    Kirti Ganorkar: No, that's not correct. I think CNS growth is also in line with India growth. If I remember correctly, it is 11% to 12% range.

  12. Question

    Vishal Manchanda: Okay. And just one final one on the tax rate, if you could give a number, what should be the tax rate this year?

    Answer, jayashree satagopan

    Jayashree Satagopan: For the full year, we can consider around 25%.

  13. Question

    Vivek Aggarwal: Hi, thanks for the opportunity. My question, first question is related to Odomzo. So, although it's a relatively smaller product in your Global Innovative Medicines pipeline, and the product was there in the market for quite some time, and in the last coup le of years, there is a sharp pickup, right? And the product has got a decent market share against the competition right? So what has changed? I just want to understand.

    Answer, richard ascroft

    Richard Ascroft: Yes, at least in the U.S., I can comment. We continue to see nice gro wth of Odomzo. It's really a recognition from clinicians of what the product can bring, and also a strong execution from our sales and marketing teams. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY26 Earnings Call Transcript 06:30 pm July 31, 2025 Vivek Aggarwal: But the product was there in the market, right, from around 2017-18, right, or 18-19, right?

  14. Question

    So is it in the last couple of years, is there any better coverage, or is there a better sales force behind the product? So have you changed anything, right, that has resulted in a sharp pickup?

    Answer, richard ascroft

    Richard Ascroft: I definitely think there's been improvement in execution with our sales team. I think also it's taken some time to convince loyalists to give the product a try, and once they give it a try, they stick with it.

  15. Question

    Vivek Aggarwal: Understood. And a related question with UNLOXCYT, right. Is it fair to assume that the channel as well as the prescribers are more or less the same for Odomzo as well as UNLOXCYT?

    Answer, richard ascroft

    Richard Ascroft: There is overlap. It's not 100% overlap, but there is overlap between the customers, which will be something we take advantage of from a sales and marketing perspective.

  16. Question

    Vivek Aggarwal: Understood. So just one more question on Leqselvi, right. If you look at the competing molecules, let's say Olumiant, right, they have a restrictive coverage like prior authorization, limited quantity, etc. So even for Leqselvi, are you expecting similar kind of coverage, or will that be enough for the pickup in this product?

    Answer, richard ascroft

    Richard Ascroft: I think with all three products, we will continue to see prior authorizations. Based on our ongoing negotiations, we do expect to have good coverage for Leqselvi versus the competition.

  17. Question

    Vivek Aggarwal: So you are expecting a better coverage for Leqselvi against the competition?

    Answer, richard ascroft

    Richard Ascroft: I think we are saying we expect at least parity coverage versus the competition.

  18. Question

    Vivek Aggarwal: Okay. And what is going to help you in, let's say, priority coverage over the competition?

    Answer, richard ascroft

    Richard Ascroft: I think really the profile of the molecule. We know from message testing that both clinicians and patients really prefer what Leqselvi has to offer, particularly from a speed perspective. And from the discussions with payers, they have been encouraged by the data we have shown them as well.

  19. Question

    Thank you for the opportunity again. Just a logistic question. So the small one-time kind of revenue that we are suggesting in ROW, is it part of innovative medicine business, or is it part of the non- innovative medicine business?

    Answer, abhishek sharma

    Abhishek Sharma: Only about ROW. Dilip Shanghvi: I understand, but it is still included in the separate number that we have given for innovative business, Global innovative business.

  20. Question

    So, that's great. One question for Rick. Since now we have seen some bit of Stelara biosimilar launches in the US market, and Europe also Stelara biosimilars have been there, so are you seeing any on-the-ground impact? Maybe new to Rx patients, given obviously biosimilar would be at a much lower cost, compared to the medicines like Ilumya or Tremfya?

    Answer, richard ascroft

    Richard Ascroft: Not really. We have not seen any major biosimilar first policies amongst payers. We also see more growth in the IL-23 class. So, there already has been movement away from Stelara in multiple therapy areas.

  21. Question

    Kunal Dhamesha: Sure. And the last one on the UNLOXCYT launch, I think we have suggested obviously it will be launched. But now, is it imminent? We should expect their launch to be in this quarter? What are we kind of waiting? Is it preparations that we are doing?

    Answer, richard ascroft

    Richard Ascroft: I can take this, Dilip, unless you want to. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY26 Earnings Call Transcript 06:30 pm July 31, 2025 Dilip Shanghvi: No, please go ahead.

    Answer, richard ascroft

    Richard Ascroft: Checkpoint had submitted long-term data for UNLOXCYT. We are currently waiting on that data to be approved and added to the label in the U.S. And once that occurs, we will launch. And of course, we are also planning for that launch, and we are dealing with that currently.

  22. Question

    Bino Pathiparampil: Okay, got it. Sir, a question on tax rate. Again, to an earlier question you answered 25%. Is that, you know, earlier you had said that your tax rate will gradually move up. Last year we had about 16%- 17%. Are you saying that this year it is going to sharply jump to 25%?

    Answer, jayashree satagopan

    Jayashree Satagopan: So, the tax rates have been moving up quarter on quarter during last year. And currently it is around 23.4%. And we expect for the full year to be around 25%.

  23. Question

    Tushar Manudhane: Sir, the reference as far as R&D spend is concerned, if it has to be so high, then at least if it is possible to share the name of the product in the subsequent list of the R&D product in the pipeline, that would be helpful. Given that the existing table which has been highlighted in the press release, most of them are up for regulatory filing.

    Answer, alok shanghvi

    Alok Shanghvi: Yes, sure. So, we currently have three facilities that are under warning letter from the US FDA. Mohali, Dadra, and Halol. We have other facilities in Baska, Ohm, Hungary, Haifa, Brampton which continue to supply to the U.S. and do not have, and we have one more facility in Billerica in the US, which is in near Boston. So, all of these facilities continue to supply and are in a compliant status with US FDA. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY26 Earnings Call Transcript 06:30 pm July 31, 2025 Tushar Manudhane: Got you.

  24. Question

    Surya Narayan Patra: Sorry for that. Second is about the Ilumya, for the new indication of psoriatic arthritis. Sir, you mentioned that the filing is likely sometime this year. But what are the likely , means how far the drug is from the commercialization i n the US? And what could be the targeted market that can be addressed by this product?

    Answer, dilip shanghvi

    Dilip Shanghvi: I mean, typically there is an approval timeline for a new indication. Hopefully, we should achieve whenever that timeline is met post the filing. I think I do not know specific target for psoriatic arthritis, but broadly, what I understand is that around 30% of the psoriasis patients also suffer from psoriatic arthritis. So, that market then becomes available to us.

  25. Question

    Yogesh Soni: Okay. So, another question that I have is I wanted to understand the Unloxcyt launch timeline. Whether it would be towards the start of second half or later part of the year?

    Answer, richard ascroft

    Richard Ascroft: We expect to launch in the second half of the fiscal year.

Questions about this call

When was the Sun Pharmaceutical Industries Q1 FY26 earnings call transcript filed?
Sun Pharmaceutical Industries filed the transcript with the exchange on 6 Aug 2025. This page is built from that transcript.
What does this page list?
42 statements from the transcript across 7 topics, 32 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 35 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Sun Pharmaceutical Industries Q1 FY26 concall: Sun Pharmaceutical Industries Limited is planning to launch UNLOXCYT in the US in the second half of FY'26 · DalalOS